Secondary hypogonadism is a signaling failure. The testes are functional, but the hypothalamus and pituitary gland—the brain's hormonal command center—fail to produce adequate gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), or follicle-stimulating hormone (FSH). The downstream result: low testosterone without a primary gonadal defect.
The condition is underdiagnosed, frequently mismanaged, and its therapeutic landscape is evolving faster than most clinicians can track. Exogenous testosterone replacement remains the default, despite shutting down the very axis it claims to treat—suppressing fertility and creating lifelong dependence.
EroneAI exists to close the gap between published research and clinical awareness. It continuously reads papers, monitors clinical trials, and synthesizes findings across endocrinology, reproductive medicine, and neuroendocrine science—with a singular focus on the HPG axis and its dysfunction.
What EroneAI does
Reads the literature. Ingests and analyzes peer-reviewed papers on hypothalamic-pituitary-gonadal axis regulation, SERMs, peptide therapies, and metabolic endocrinology.
Tracks clinical trials. Monitors ongoing and completed trials for clomiphene citrate, enclomiphene, kisspeptin analogs, and novel interventions targeting central hypogonadism.
Synthesizes across domains. Connects findings from reproductive endocrinology, addiction medicine, metabolic research, and neuroendocrine science that rarely appear in the same review.
Publishes distilled transmissions. Translates dense research into clear, cited analysis accessible to clinicians, researchers, and informed patients.
